These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30055648)

  • 1. Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.
    Fischer-Huchzermeyer S; Chikobava L; Stahn V; Zangarini M; Berry P; Veal GJ; Senner V; Mautner VF; Harder A
    BMC Res Notes; 2018 Jul; 11(1):520. PubMed ID: 30055648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.
    Fischer-Huchzermeyer S; Dombrowski A; Wilke G; Stahn V; Streubel A; Mautner VF; Harder A
    PLoS One; 2017; 12(11):e0187700. PubMed ID: 29131833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
    Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
    Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
    Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
    J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Calizo A; Pratilas CA
    Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
    Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
    Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.
    Kendall JJ; Chaney KE; Patel AV; Rizvi TA; Largaespada DA; Ratner N
    Oncotarget; 2016 Aug; 7(33):53191-53203. PubMed ID: 27448963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.
    Castellsagué J; Gel B; Fernández-Rodríguez J; Llatjós R; Blanco I; Benavente Y; Pérez-Sidelnikova D; García-Del Muro J; Viñals JM; Vidal A; Valdés-Mas R; Terribas E; López-Doriga A; Pujana MA; Capellá G; Puente XS; Serra E; Villanueva A; Lázaro C
    EMBO Mol Med; 2015 May; 7(5):608-27. PubMed ID: 25810463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
    Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
    Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
    Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
    Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor.
    Ikuta K; Ota T; Zhuo L; Urakawa H; Kozawa E; Hamada S; Kimata K; Ishiguro N; Nishida Y
    Int J Cancer; 2017 Jan; 140(2):469-479. PubMed ID: 27706810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
    Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
    Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
    El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
    J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs).
    Demestre M; Terzi MY; Mautner V; Vajkoczy P; Kurtz A; Piña AL
    J Neurooncol; 2013 Dec; 115(3):391-9. PubMed ID: 24078214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Sweeney EE; Burga RA; Li C; Zhu Y; Fernandes R
    Sci Rep; 2016 Nov; 6():37035. PubMed ID: 27833160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.
    Chau V; Lim SK; Mo W; Liu C; Patel AJ; McKay RM; Wei S; Posner BA; De Brabander JK; Williams NS; Parada LF; Le LQ
    Cancer Res; 2014 Jan; 74(2):586-97. PubMed ID: 24285727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.